Literature DB >> 20149600

Lennox-Gastaut syndrome in adulthood: clinical and EEG features.

Edoardo Ferlazzo1, Marina Nikanorova, Marina Nikaronova, Domenico Italiano, Michelle Bureau, Charlotte Dravet, Tiziana Calarese, Danielle Viallat, Margarethe Kölmel, Placido Bramanti, Lorenzo De Santi, Pierre Genton.   

Abstract

PURPOSE: We performed a retrospective study to investigate seizure, EEG, social and cognitive outcome in adult LGS subjects.
METHODS: We retrospectively evaluated 27 LGS patients aged 40-59 years. We assessed in particular the evolution of different seizure types and EEG findings, as well as cognitive and social outcome.
RESULTS: During the early stages of the disease, all patients presented tonic seizures (TS) during wakefulness and sleep, 20/27 had atypical absences (AA), more rarely other seizure types. EEG showed slow background activity in 21/27 patients, diffuse slow spike-wave discharges (DSSW) during wakefulness in 22/27, and bursts of diffuse fast rhythms (DFR) in sleep in all patients. At last observation, 11 patients only had TS during wakefulness, but all still presented TS during sleep; AA persisted in 6 patients. EEG showed normal BA in 12/27 patients; only 7/27 still presented DSSW. On the contrary, sleep EEG showed the persistence of DFR in all. A moderate to severe cognitive impairment was observed in 26/27 patients.
CONCLUSIONS: In adult LGS patients TS during sleep remain the major seizure type; moreover, a standard waking EEG may be normal. Thus, polysomnography represents the most important mean of investigation also in adult LGS patients. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20149600     DOI: 10.1016/j.eplepsyres.2010.01.012

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  11 in total

1.  Corticothalamic network dysfunction and Alzheimer's disease.

Authors:  Rohan Jagirdar; Jeannie Chin
Journal:  Brain Res       Date:  2017-09-15       Impact factor: 3.252

Review 2.  Lennox-Gastaut syndrome: a comprehensive review.

Authors:  Ali A Asadi-Pooya
Journal:  Neurol Sci       Date:  2017-11-09       Impact factor: 3.307

Review 3.  Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.

Authors:  Katherine C Nickels; Michael J Zaccariello; Lorie D Hamiwka; Elaine C Wirrell
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

4.  Late-onset Lennox-Gastaut syndrome: Diagnostic evaluation and outcome.

Authors:  Kelsey M Smith; Jeffrey W Britton; Gregory D Cascino
Journal:  Neurol Clin Pract       Date:  2018-10

5.  Anti-seizure medications for Lennox-Gastaut syndrome.

Authors:  Francesco Brigo; Katherine Jones; Christin Eltze; Sara Matricardi
Journal:  Cochrane Database Syst Rev       Date:  2021-04-07

Review 6.  Electroencephalogram of age-dependent epileptic encephalopathies in infancy and early childhood.

Authors:  Lily C Wong-Kisiel; Katherine Nickels
Journal:  Epilepsy Res Treat       Date:  2013-08-19

Review 7.  Lennox-Gastaut syndrome. Management update.

Authors:  Muradi H Al-Banji; Doaa K Zahr; Mohammed M Jan
Journal:  Neurosciences (Riyadh)       Date:  2015-07       Impact factor: 0.906

8.  Challenges in identifying Lennox-Gastaut syndrome in adults: A case series illustrating its changing nature.

Authors:  Jesus Eric Piña-Garza; Steve Chung; Georgia D Montouris; Rodney A Radtke; Trevor Resnick; Robert T Wechsler
Journal:  Epilepsy Behav Case Rep       Date:  2016-02-11

9.  Brainstem dysfunction in patients with late-onset Lennox-Gastaut syndrome: Voxel-based morphometry and tract-based spatial statistics study.

Authors:  Kang Min Park; Yun Jung Hur; Sung Eun Kim
Journal:  Ann Indian Acad Neurol       Date:  2016 Oct-Dec       Impact factor: 1.383

Review 10.  Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations.

Authors:  J Helen Cross; Stéphane Auvin; Mercè Falip; Pasquale Striano; Alexis Arzimanoglou
Journal:  Front Neurol       Date:  2017-09-29       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.